| Ny Metro Dental, Pc | |
|
966 Portion Rd Ronkonkoma NY 11779-1986 | |
| (413) 382-7022 | |
| Not Available |
| Full Name | Ny Metro Dental, Pc |
|---|---|
| Speciality | Dentist |
| Location | 966 Portion Rd, Ronkonkoma, New York |
| Authorized Official Name and Position | Amy Cadieux (REG MGR) |
| Authorized Official Contact | 4133827022 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Ny Metro Dental, Pc 330 Whitney Ave Ste 740 Holyoke MA 01040-2789 Ph: () - | Ny Metro Dental, Pc 966 Portion Rd Ronkonkoma NY 11779-1986 Ph: (413) 382-7022 |
| NPI Number | 1265066567 |
|---|---|
| Provider Enumeration Date | 02/25/2020 |
| Last Update Date | 02/25/2020 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265066567 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | (* (Not Available)) | Primary |
News Archive
NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.
In comments submitted to the Centers for Medicare and Medicaid Services, the American College of Rheumatology expressed its continuing concern with a recent CMS policy allowing Medicare Advantage plans to utilize step therapy for Part B drugs.
KineMed, Inc. and CHDI Foundation, Inc. announced today an extension of their collaboration that uses KineMed's translational biomarker platform to characterize and track the pathogenesis of Huntington's disease (HD) and evaluate potentially therapeutic interventions.
Results from a preliminary study indicate that among patients with relapsing-remitting multiple sclerosis (MS), treatment with nonmyeloablative hematopoietic stem cell transplantation (low intensity stem cell transplantation) was associated with improvement in measures of disability and quality of life, according to a study in the January 20 issue of JAMA.
An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.
› Verified 8 days ago
Dental 365 Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 217 Portion Rd, Ronkonkoma, NY 11779 Phone: 631-588-4860 | |
Concerned Dental Care Of Ronkonkoma, Pllc Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 966 Portion Road, Ronkonkoma, NY 11779 Phone: 631-451-2245 | |
Dental Smiles For Kids Ronkonkoma Dental Clinic Medicare: Not Enrolled in Medicare Practice Location: 500 Portion Rd Ste 216, Ronkonkoma, NY 11779 Phone: 631-451-7700 |